FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Guide on Device Definition in Regulatory Documents

Federal Register notice: FDA makes available a final guidance entitled Referencing the Definition of a Device in the Federal Food, Drug, and Cosmetic ...

latest-news-card-1
Federal Register

Regulatory Review Period for Mercks Prevymis

Federal Register notice: FDA determines for patent term extension purposes the regulatory review period for Mercks Prevymis (letermovir) intravenous s...

latest-news-card-1
Federal Register

Guide on Biotech Product Viral Safety Evaluations

Federal Register notice: FDA makes available a draft guidance entitled Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lin...

latest-news-card-1
Human Drugs

Satsuma Plans Migraine NDA After Data Miss

Satsuma Pharmaceuticals says topline results from the STS101 SUMMIT Phase 3 efficacy trial showed numerical differences in favor of its migraine drug ...

latest-news-card-1
Biologics

ImmunoGens Elahere OKd for Several Cancers

FDA grants ImmunoGen an accelerated approval for Elahere (mirvetuximab soravtansine-gynx) for treating certain adult patients with folate receptor alp...

latest-news-card-1
Medical Devices

Insulet Device Correction on Melting Omnipod 5

Insulet issues a Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System because of an overheating issue with the Omnipod 5 Cont...

latest-news-card-1
Federal Register

Regulatory Review Period for Mercks Prevymis

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Mercks Prevymis (letermovir).

Federal Register

Info Collection on Social/Behavioral Research

Federal Register notice: FDA sends to OMB an information collection extension entitled Data to Support Social and Behavioral Research as Used by the F...

latest-news-card-1
Federal Register

Comment Period Extended on IRB Proposed Rules

Federal Register notice: FDA extends by two months the comment period on two proposed rules that appeared in the 9/28 Federal Register.

latest-news-card-1
Human Drugs

GSK Narrows Zejula Indication at FDAs Request

GSK says it has complied with an FDA request to restrict the second-line maintenance indication for cancer drug Zejula (niraparib).